Skip to content

Three Quick Facts: GlaxoSmithKline, Novacyt and Ryanair

*

Three things you need to know in the financial markets this morning from investment writer, Tony Cross.

GlaxoSmithKline

There’s a note out form GlaxoSmithKline LON:GSK this morning regarding its COVID vaccination program. The company is clearly lagging other big names here, but the success if its phase 2 trail means the product is moving to phase 3. There’s a bit of detail to wade through in the note but one line that stands out is its potential application as a booster dose, something that could prove increasingly important given the occurrence of variants.

Novacyt

Keeping with the health sector, there’s a note from AIM-listed Novacyt [LON:NCYT], announcing that its PCR geotyping portfolio has been included in NHS England’s Variant of Concern framework. There’s no detail here as to the value of this deal, but with healthcare providers globally set to be watching for mutations of the virus for some time – and the stock languishing well below highs seen over the winter – this news could well receive a positive response from investors.

Ryanair

Full year results are out from Ryanair [LON:RYA] this morning, with a record EUR815 million loss having been recorded. However the carrier believes the recovery has already taken off, with booking having risen from around 500,000 a week at the end of April to a current rate of 1,500,000. If the European vaccine rollout remains on track then the airline believes it could be close to break even for the financial year to March 2022, where it expects to carry between 80 million and 120 million passengers. To put that in context, 27.5 million flew this year and in the 12 months to March 2020, some 149 million passengers boarded Ryanair flights.

Sign up for three quick facts and more with our Free Daily Digest newsletter, every weekday morning.

Looking for great investing ideas? Sign up to our free newsletter.

Join us on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone

TMX
WisdomTree
IG
FxPro
Back To Top